Femoston as a hormone replacement therapy for ovarian failure

The article presents the results of a number of hemostasis parameters (coagulation, vascular and thrombocytic) and lipoprotein spectra, including apo A-1 and apo B₁₀₀ apoproteins against the background of hormone replacement treatment with Femostone (Solvay, Germany). The results were compared taking into account menstrual cycle phases in perimenopausal patients (with a preserved cycle) and conditional estrogenic, progestagenic phases of Femostone administration. The advantages of the progestagen didrogesterone included in the drug in its effect on the lipid spectrum, apoproteins and some parameters of vascular thrombocyte hemostasis are shown.